Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Janux Therapeutics, Inc.NASDAQ: JANX

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures dips below year-ago levels

Q1 FY2026 capital expenditures of $273K (cash outflow) fell 26.4% year over year, behind the +77.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 157.5% from the prior quarter. Over 3 fiscal years it compounded at -45.5% a year.

Context

  • Capital expenditures amounted to 10.4% of revenue in FY2025, up 7.0 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -26.4% toward the trailing-twelve-month pace of +77.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$273K+157.5% QoQ
Last fiscal yearDec 2025
-$1.04M+190.5% YoY
LTMMar 2026
-$945K+77.3% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.4%——
1 year+190.5%——
3-year CAGR-45.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.04M) USD
Year-over-year change
-190.5%

Capital Expenditures vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +77.3% is the 3rd highest of 9, against a peer median of -0.4%.
  • Capital expenditures amounts to 4.4% of revenue for JANX, versus a peer median of 3.2%.
JANX Competitors
Capital Expenditures for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$73.11M USD+292.9%+44.8%5.4%
IMNMImmunome, Inc.LTM Sep 2026$9.67M USD+36.9%+239.3%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$7.48M USD+241.6%+14.1%6676.8%
IMTXImmatics N.V.LTM Mar 2026€4.36M EUR-58.3%+0.4%11.7%
MGNXMacroGenics, Inc.LTM Mar 2026$1.73M USD-37.7%-19.2%1.1%
JANXJanux Therapeutics, Inc.LTM Mar 2026$945K USD+77.3%-45.5%4.4%
STROSutro Biopharma, Inc.LTM Mar 2026$532K USD-86.1%-40.0%0.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$101K USD-67.8%-49.8%0.3%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$89K USD+43.5%-51.0%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$11K USD—-64.9%—
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —-0.4%-19.2%3.2%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Depreciation & Amortization113K841K1.96M2.06M2.03M
Deferred Income Tax00000
Stock-Based Compensation6.91M17.2M20.01M33.02M40.22M
Change in Working Capital8.84M4.28M(6.55M)685K6.71M
Accounts Receivables8M0000
Inventory831K0000
Accounts Payables2.14M(294K)277K1.58M977K
Other Working Capital(2.13M)4.57M(6.83M)(899K)5.74M
Other Non-Cash Items(169K)(2.18M)(7.69M)(10.59M)(17.57M)
Operating Cash Flow(16.98M)(42.92M)(50.58M)(43.81M)(82.24M)
Capital Expenditures(1.48M)(6.45M)(1.85M)(359K)(1.04M)
Acquisitions (Net)339.48M(64.71M)000
Purchases of Investments(473.63M)(294.39M)(317.34M)(470.58M)(705.22M)
Sales of Investments134.15M359.1M278M212.92M405.28M
Other Investing Activities(339.48M)64.71M000
Investing Cash Flow(340.96M)58.27M(41.19M)(258.02M)(300.98M)
Debt Repayment00000
Common Stock Issued204.17M500K56.53M698.27M5.29M
Common Stock Repurchased0000(347K)
Dividends Paid00000
Other Financing Activities1.81M03.02M14.97M0
Financing Cash Flow386.52M500K59.55M713.24M4.95M
Effect of Forex Changes00000
Net Change in Cash28.59M15.84M(32.22M)411.4M(378.27M)
Free Cash Flow(18.46M)(49.37M)(52.43M)(44.17M)(83.28M)

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.